Bristol Myers Squibb, Eli Lilly and Novo are among the limited partners in the pharmaceutical-focused venture firm's BGV IV fund, which has reached its final close.
Netherlands-based, healthcare-focused venture capital firm BioGeneration Ventures has closed its fourth fund at €140m (roughly $170m) having picking up commitments from pharmaceutical companies Eli Lilly, Bristol Myers Squibb (BMS) and Novo. Novo backed the fund through corporate VC vehicle Novo Ventures, and Schroder Adveq, Industriens Pension, KfW Capital and European Investment Fund (EIF) are also…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.